Latest Options News

Lotus Resources has fast-tracked the restart of its Kayelekera uranium project in Malawi, targeting production by Q3 2025, backed by a $132 million capital raise. Meanwhile, its Letlhakane project in Botswana reports a 65% increase in measured and indicated uranium resources.

Austral Gold reported an 8.5% production increase in Q4 2024 alongside significant cost reductions, though full-year output fell short of forecasts due to equipment delays. The company sets ambitious 2025 targets, supported by a new toll processing deal and plant refurbishment financing.

Australian Strategic Materials (ASM) has secured a $5 million federal grant to accelerate its Dubbo Project, progressing rare earth recovery innovations while navigating a complex global market landscape.

Buxton Resources reports robust drilling results at its Graphite Bull and Narryer projects, completes Stage 1 earn-in on Copper Wolf JV with IGO, and undertakes key board changes, positioning itself for an active 2025 exploration season.

Kuniko Limited's December 2024 quarterly report reveals a significant resource upgrade at its flagship Ertelien project, alongside promising copper-zinc targets in Trøndelag, reinforcing its role in Europe's sustainable battery metals supply chain.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Rimfire Pacific Mining's December 2024 quarterly report reveals its highest-grade scandium intercept to date at Murga and strategic expansion with the Rabbit Trap Scandium Project acquisition, alongside promising cobalt-copper results at Broken Hill.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Ronin Resources has made significant strides in its exploration portfolio, applying for a large gold-silver project in Argentina and raising $461,500 to fund its development. The company also reports steady cash reserves and ongoing efforts to expand its business opportunities.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

MedAdvisor Limited reported a significant 38.6% drop in 2Q FY25 revenue due to vaccine program deferrals but expects a stronger second half driven by a diversified US pipeline and cost-saving initiatives.